The association between obesity, cardiometabolic disease biomarkers, and innate immunity-related inflammation in canadian adults

Diabetes, Metabolic Syndrome and Obesity

Volumn 5, Issue , 2012, Pages 347-355

  da Costa, Laura A ^a,b   Arora, Paul ^a,b   García Bailo, Bibiana ^a,b   Karmali, Mohamed ^a,b   El Sohemy, Ahmed ^a   Badawi, Alaa ^b  

^a UNIVERSITY OF TORONTO   (Canada)

^b PUBLIC HEALTH AGENCY OF CANADA   (Canada)

Author keywords

Biomarkers; Cardiometabolic disease; Inflammation; Obesity

Indexed keywords

25 HYDROXYVITAMIN D; APOLIPOPROTEIN A1; APOLIPOPROTEIN B; C REACTIVE PROTEIN; FIBRINOGEN; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HOMOCYSTEINE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL;

ADULT; AGE; AGED; ARTICLE; BODY MASS; BODY WEIGHT DISORDER; CANADIAN; CARDIOMETABOLIC DISEASE; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE MARKER; ETHNIC GROUP; ETHNICITY; FEMALE; HEALTH SURVEY; HEART DISEASE; HUMAN; INFLAMMATION; INNATE IMMUNITY; LINEAR REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; MEASUREMENT; METABOLIC DISORDER; OBESITY; PHYSICAL ACTIVITY; SEX; SMOKING;

EID: 84872301746     PISSN: 11787007     EISSN: None     Source Type: Journal    
DOI: 10.2147/dmso.s35115     Document Type: Article

References (46)

1. Public Health Agency of Canada. Obesity in Canada: A Joint Report from the Public Health Agency of Canada and the Canadian Institute for Health Information; 2011. Available from: http://www.phac-aspc.gc.ca/hp-ps/hl-mvs/oic-oac/index-eng.php. Accessed August 13, 2012.
2. Guh DP, Zhang W, Bansback N, Amarsi Z, Birmingham CL, Anis AH. The incidence of co-morbidities related to obesity and overweight: a systematic review and meta-analysis. BMC Public Health. 2009; 9:88.
3. Fontaine KR, Barofsky I. Obesity and health-related quality of life. Obes Rev. 2001;2(3):173-182.
4. Badawi A, Klip A, Haddad P, Cole DE, Garcia-Bailo B, El-Sohemy A, et al. Type 2 diabetes mellitus and inflammation: Prospects for biomarkers of risk and nutritional intervention. Diabetes Metab Syndr Obes. 2010;3:173-186.
5. Van Gaal LF, Mertens IL, De Block CE. Mechanisms linking obesity with cardiovascular disease. Nature. 2006;444(7121):875-880.
6. Bray GA, Clearfield MB, Fintel DJ, Nelinson DS. Overweight and obesity: the pathogenesis of cardiometabolic risk. Clin Cornerstone. 2009;9(4):30-40.
7. Hotamisligil GS. Inflammation and metabolic disorders. Nature. 2006; 444(7121):860-867.
8. Danesh J, Collins R, Appleby P, Peto R. Association of fibrinogen, C-reactive protein, albumin, or leukocyte count with coronary heart disease: meta-analyses of prospective studies. JAMA. 1998;279(18): 1477-1482.
9. Ridker PM. Inflammatory biomarkers and risks of myocardial infarction, stroke, diabetes, and total mortality: implications for longevity. Nutr Rev. 2007;65(12 Pt 2):S253-S259.
10. García-Bailo B, El-Sohemy A, Haddad PS, et al. Vitamins D, C, and E in the prevention of type 2 diabetes mellitus: modulation of inflammation and oxidative stress. Biologics. 2011;5:7-19.
11. Brenner DR, Arora P, García-Bailo B, et al. Plasma vitamin D levels and risk of metabolic syndrome in Canadians. Clin Invest Med. 2011; 34(6):E377.
12. Brenner DR, Arora P, García-Bailo B, et al. The relationship between metabolic syndrome and markers of cardiometabolic disease among Canadian adults. J Diabetes Metab. 2011;S2:3.
13. Tremblay M, Wolfson M, Gorber SC. Canadian Health Measures Survey: rationale, background and overview. Health Rep. 2007;18 Suppl:S7-S20.
14. Bryan S, St-Denis M, Wojtas D. Canadian Health Measures Survey: clinic operations and logistics. Health Rep. 2007;18 Suppl:S53-S70.
15. Day B, Langlois R, Tremblay M, Knoppers BM. Canadian Health Measures Survey: ethical, legal and social issues. Health Rep. 2007;18 Suppl:S37-S51.
16. Giroux S. Canadian Health Measures Survey: sampling strategy overview. Health Rep. 2007;18 Suppl:S31-S36.
17. Health Canada. Canadian Guidelines for Body Weight Classification in Adults; 2003. Available from: http://www.hc-sc.gc.ca/fn-an/nutrition/weights-poids/guide-ld-adult/index-eng.php. Accessed August 13, 2012.
18. Shields M, Tremblay MS, Laviolette M, Craig CL, Janssen I, Gorber SC. Fitness of Canadian adults: results from the 2007-2009 Canadian Health Measures Survey. Health Rep. 2010;21(1):21-35.
19. Miller WM, Nori-Janosz KE, Lillystone M, Yanez J, McCullough PA. Obesity and lipids. Curr Cardiol Rep. 2005;7(6):465-470.
20. Bamba V, Rader DJ. Obesity and atherogenic dyslipidemia. Gastroenterology. 2007;132(6):2181-2190.
21. Carr MC, Brunzell JD. Abdominal obesity and dyslipidemia in the metabolic syndrome: importance of type 2 diabetes and familial combined hyperlipidemia in coronary artery disease risk. J Clin Endocrinol Metab. 2004;89(6):2601-2607.
22. Zhong L, Li Q, Jiang Y et al. The ApoB/ApoA1 ratio is associated with metabolic syndrome and its components in a Chinese population. Inflammation. 2010;33:353-358.
23. Walldius G, Jungner I. Apolipoprotein A-I versus HDL cholesterol in the prediction of risk for myocardial infarction and stroke. Curr Opin Cardiol. 2007;22(4):359-367.
24. Barter PJ, Ballantyne CM, Carmena R, et al. Apo B versus cholesterol in estimating cardiovascular risk and in guiding therapy: a report of the thirty-person/ten-country panel. J Intern Med. 2006;259(3):247-258.
25. Florvall G, Basu S, Larsson A. Apolipoprotein A1 is a stronger prognostic marker than are HDL and LDL cholesterol for cardiovascular disease and mortality in elderly men. J Gerontol Ser A Biol Sci Med Sci. 2006;61(12):1262-1266.
26. Wu JT. Circulating homocysteine is an inflammation marker and a risk factor of life-threatening inflammatory diseases. J Biomed Lab Sci. 2007;19(4):107-111.
27. Martí-Carvajal AJ, Solà I, Lathyris D, Salanti G. Homocysteine lowering interventions for preventing cardiovascular events. Cochrane Database Syst Rev. October 7, 2009;4:CD006612.
28. Abraham JM, Cho L. The homocysteine hypothesis: still relevant to the prevention and treatment of cardiovascular disease? Cleve Clin J Med. 2010;77(12):911-918.
29. Nguyen XM, Lane J, Smith BR, Nguyen NT. Changes in inflammatory biomarkers across weight classes in a representative US population: a link between obesity and inflammation. J Gastrointest Surg. 2009;13(7):1205-1212.
30. Papandreou D, Mavromichalis I, Makedou A, Rousso I, Arvanitidou M. Total serum homocysteine, folate and vitamin B12 in a Greek school age population. Clin Nutr. 2006;25(5):797-802.
31. Nakazato M, Maeda T, Takamura N, et al. Relation of body mass index to blood folate and total homocysteine concentrations in Japanese adults. Eur J Nutr. 2011;50(7):581-585.
32. Matsuzawa Y, Funahashi T, Nakamura T. The concept of metabolic syndrome: contribution of visceral fat accumulation and its molecular mechanism. J Atheroscler Thromb. 2011;18(8):629-639.
33. Ghanim H, Aljada A, Hofmeyer D, Syed T, Mohanty P, Dandona P. Circulating mononuclear cells in the obese are in a proinflammatory state. Circulation. 2004;110(12):1564-1571.
34. Pfützner A, Schöndorf T, Tschöpe D, et al. PIOfix-study: effects of pioglitazone/metformin fixed combination in comparison with a combination of metformin with glimepiride on diabetic dyslipidemia. Diabetes Technol Ther. 2011;13(6):637-643.
35. American Diabetes Association. Executive summary: Standards of medical care in diabetes - 2010. Diabetes Care. 2010;33 Suppl 1:S4-S10.
36. Zajacova A, Dowd JB, Burgard SA. Overweight adults may have the lowest mortality - do they have the best health? Am J Epidemiol. 2011; 173(4):430-437.
37. Boeing H, Weisgerber UM, Jeckel A, Rose H-J, Kroke A. Association between glycated hemoglobin and diet and other lifestyle factors in a nondiabetic population: cross-sectional evaluation of data from the Potsdam cohort of the European Prospective Investigation into Cancer and Nutrition Study. Am J Clin Nutr. 2000;71(5):1115-1122.
38. Koga M, Matsumoto S, Saito H, Kasayama S. Body mass index negatively influences glycated albumin, but not glycated hemoglobin, in diabetic patients. Endocr J. 2006;53(3):387-391.
39. Mai XM, Chen Y, Camargo CA Jr, Langhammer A. Cross-sectional and prospective cohort study of serum 25-hydroxyvitamin D level and obesity in adults: The HUNT study. Am J Epidemiol. 2012;175(10): 1029-1036.
40. Brock K, Huang WY, Fraser DR, et al. Low vitamin D status is associated with physical inactivity, obesity and low vitamin D intake in a large US sample of healthy middle-aged men and women. J Steroid Biochem Mol Biol. 2010;121(1/2):462-466.
41. Young KA, Engelman CD, Langefeld CD, et al. Association of plasma vitamin D levels with adiposity in Hispanic and African Americans. J Clin Endocrinol Metab. 2009;94(9):3306-3313.
42. Hyppönen E, Power C. Hypovitaminosis D in British adults at age 45 y: nationwide cohort study of dietary and lifestyle predictors. Am J Clin Nutr. 2007;85(3):860-868.
43. Snijder MB, van Dam RM, Visser M, et al. Adiposity in relation to vitamin D status and parathyroid hormone levels: a population-based study in older men and women. J Clin Endocrinol Metab. 2005;90(7):4119-4123.
44. Wortsman J, Matsuoka LY, Chen TC, Lu Z, Holick MF. Decreased bioavailability of vitamin D in obesity. Am J Clin Nutr. 2000;72(3): 690-693.
45. McCarty MF, Thomas CA. PTH excess may promote weight gain by impeding catecholamine-induced lipolysis-implications for the impact of calcium, vitamin D, and alcohol on body weight. Med Hypotheses. 2003;61(5/6):535-542.
46. Veldman CM, Cantorna MT, DeLuca HF. Expression of 1,25-dihydroxyvitamin D(3) receptor in the immune system. Arch Biochem Biophys. 2000;374(2):334-338.